Skip to main content

What the FDA labels say about taking them together

Carbamazepine and vemurafenib

Vemurafenib's FDA label of August 28, 2026 names carbamazepine in its drug interactions section; the carbamazepine labels PlainMeds reads (3) do not name vemurafenib. The vemurafenib label: “Avoid coadministration of ZELBORAF with strong CYP3A4 inducers, and replace these drugs with alternative drugs when possible.”

Check it at the source: the carbamazepine FDA label on DailyMed (effective August 20, 2026, Novartis Pharmaceuticals Corporation); the vemurafenib FDA label on DailyMed (effective August 28, 2026, Genentech, Inc.).

What does the carbamazepine label say about vemurafenib?

Carbamazepine's label (effective August 20, 2026) and its 2 other brand-application labels do not name vemurafenib in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Tegretol), Novartis Pharmaceuticals Corporation, effective August 20, 2026 (SPL set 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053), via openFDA; the full label on DailyMed

What does the vemurafenib label say about carbamazepine?

Vemurafenib label, drug interactions

Avoid coadministration of ZELBORAF with strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin), and replace these drugs with alternative drugs when possible.

Source: FDA drug label (ZELBORAF), NDA202429 (Hoffmann La Roche), as published by Genentech, Inc., effective August 28, 2026 (SPL set 38eea320-7e0c-485a-bc30-98c3c45e2763), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

42Carbamazepine generic labelers
0Vemurafenib generic labelers
CarbamazepineVemurafenib
Labeled forBipolar disorder, Seizures and epilepsyn/a
Boxed warningYesNo
Pharmacy cost (NADAC)$0.119 per tablet 200 mg tabletn/a
Shortage nowA presentation being discontinuedNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?